Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
April 2025
The global nuclear medicine market size accounted at USD 13.21 billion in 2025 and is predicted to surpass around USD 35.04 billion by 2034, representing a healthy CAGR of 11.45% between 2025 and 2034. The North America nuclear medicine market size is calculated at USD 5.69 billion in 2024 and is expected to grow at a fastest CAGR of 11.56% during the forecast year. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global nuclear medicine market size was estimated at USD 11.85 billion in 2024 and is anticipated to reach around USD 35.04 billion by 2034, expanding at a CAGR of 11.45% from 2025 to 2034. The market is boosted due to several reasons such as rising prevalence of chronic diseases such as cancer and cardiovascular conditions and technological developments in nuclear imaging and radiopharmaceuticals practices.
AI plays a significant role in the diagnosis and therapeutic process which results in the development of the nuclear medicine market. It can help to gather all the information and medical issues associated with the patient and help to plan a personalized treatment strategy for specific requirements. With the incorporation of AI in this market patients' responses can be easily predicted towards any therapy which allows the professionals to understand more about the health condition of the patient. It can help to detect the effect of therapies which help to decide further treatment plans.
The U.S. nuclear medicine market size was reached USD 3.98 billion in 2024 and is anticipated to be worth around USD 11.98 billion by 2034, poised to grow at a CAGR of 11.65% from 2025 to 2034.
On the basis of geography the nuclear medicine market segment will have the largest market share of 48% in the North American region. This market is expected to have a dominant position due to the presence of various manufacturing units in this region. The availability of the best healthcare infrastructure in this region add the adoption of the procedures that include the use of nuclear medicine will drive the market growth in the North American region.
In order to manufacture different radiopharmaceuticals many facilities are developing in the North American region. Radioisotopes of the commercial stage are produced in the North American region. There has been a growth in the demand for these radioisotopes and radionuclides even in the Asia Pacific region.
Leading the Charge in Radiopharmaceutical Innovation
North America dominates the market due to High investment in research and advanced nuclear imaging facilities has placed the U.S. at the forefront of the nuclear medicine market. Strong collaboration between universities and biotech firms fuels rapid innovation in diagnostics and therapy. Government bodies like the Department of Energy and the National Institutes of Health have extended funding for isotope development and cancer research programs. The second most key player, Canada, is renowned for its contributions to clean and non-reactor-based isotope production. Institutions like TRIUMF and Nordion lead in radioisotope generation through cyclotrons, reducing environmental risk. Canadian health agencies are supporting nationwide PET scan infrastructure and molecular imaging research.
The U.S. is experiencing rapid growth in the nuclear medicine market due to increasing prevalence of chronic diseases, advancements in imaging techniques, and government initiatives supporting research and healthcare infrastructure. Early detection and tailored treatment plans enabled by nuclear medicine are becoming more important as the population ages and the burden of chronic diseases increases. The nuclear medicine provides precise diagnostic capabilities for early detection and personalized treatment plans using imaging modalities such as PET and SPECT scans. Additionally, Increased awareness of the benefits of early diagnosis and treatment is driving demand for nuclear medicine procedures. The U.S. is a significant exporter of nuclear medicines with export destinations such as Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa, and countries in the European Union (EU) and the European Economic Area (EEA).
The Canadian nuclear medicine market is expected to grow due to increasing occurrence of cancer and cardiovascular diseases which are major health concerns in Canada. Nuclear medicine plays a crucial role in their diagnosis and treatment where early detection, often facilitated by nuclear imaging, can significantly improve treatment outcomes. A robust regulatory framework, along with strong production capabilities, has positioned North America, including Canada, as a leader in the global nuclear medicine market.
Asia Pacific witnessed the fastest-growing region in forecast year. This is majorly due to the rising awareness about nuclear medicine and growing investment in this field. People becoming aware of the effectiveness of therapies such as radiopharmaceuticals mainly in oncology, and there is a huge demand due to its rising treatment for such chronic diseases. The rising number of cancer cases worldwide has compelled market players to bring innovation to the nuclear medicine market. With the growing investment of the government in the healthcare sector result in rapid growth of this market.
The Chinese government is actively promoting the development of nuclear medicine within its healthcare reforms including increasing government spending on nuclear medicine facilities, research and development, and infrastructure, leading to a surge in nuclear medicine departments in hospitals. Technological developments in nuclear medicine, such as the development of new radiopharmaceuticals and imaging techniques, are contributing to the growth of the market. China is also making significant investments in radiopharmaceutical research and development which aims to become a leader in this field. China's involvement in international collaborations and standardization efforts in nuclear medicine is also contributing to its growth and aims to improve healthcare outcomes and access to advanced technologies.
India has a high incidence of cancer resulting in increased demand for advanced diagnostic tools such as PET/CT scans and are crucial for early detection and staging of cancer. Nuclear imaging techniques are used to diagnose and monitor conditions such as heart disease, strokes, and Alzheimer's, driving demand in these areas as well. The increasing number of PET/CT imaging centers across India makes these advanced imaging techniques more accessible to a wider population. The availability of trained nuclear medicine technologists and specialists is enough for the effective operation of nuclear medicine departments.
Asia-Pacific The New Hotspot for Nuclear Healthcare
Asia-Pacific, known to be the new hotspot for nuclear healthcare, is the reason for the fastest growth due to Rapid urbanisation and rising healthcare investment are pushing the demand for nuclear medicine in countries like India, China, South Korea, and Japan. Government initiatives are focused on expanding nuclear medicine facilities in tier-2 cities, ensuring wider access. Increased participation in clinical trials, international collaborations, and a growing pharmaceutical base are supporting the market. Demand for affordable radiopharmaceuticals and indigenous production has encouraged technological self-sufficiency. Expanding cancer care centres and cardiac facilities
The nuclear medicine is the field which uses very less quantity of radiology or different materials of radioactive nature in order to observe the structure or sometimes the functioning of an organ in the human body. It is largely used for different types of illnesses that need the diagnosis and the treatment through the use of nuclear medicine. The treatment is done through the use of radiopharmaceuticals. There are different types of illnesses that need this type of treatment like thyroid cancer, different types of bone pain or hyperthyroidism.
In the field of nuclear medicine different types of images are created with the help of the internal type of radiations which are in the form of waves in the body. This nuclear imaging is suggested by doctors in order to detect cancer or different types of tumors that have spread in the body of the patient. It is extremely helpful in determining the course of treatment or in understanding the treatment that may be required for a particular patient. There are very small risks that are associated with this type of medicine which could be in the form of allergic reactions. The shelf life of radioisotopes is extremely less. If these radioisotopes are not utilized in the specific period of time it leads to the chemical decomposition of these radioisotopes. Which hampers the purity of the radiochemical to such an extent that the use of such a chemical in the therapeutics or diagnosis of any illness would turn out to be fatal. There are different shelf lives of different products.
Some of these products need to be used in the time frame of 110 minutes while there are others that start decomposing in 20 minutes. There are a few other types of products that start perishing in a time frame of six hours and there are few others that can be utilized before 67 hours. The type of equipment required for this type of detection and treatments are extremely expensive which happens to hamper the growth of the market. The use of this type of equipment increases the budget of various hospitals thereby making the treatment and the detection of cardiovascular diseases as well as cancer extremely expensive which happens to be another barrier in the growth of the market.
Increase in the geriatric population across the globe in the developing as well as the developed economies there has been an increase in the number of cardiovascular diseases. This increased number of cardiovascular diseases in the geriatric population has created a great demand for the use of nuclear medicine. There has also been an increase in the number of cancer patients across the globe which happens to be a major illness that requires the use of nuclear medicines. In order to detect cancer and to treat cancer this type of medicine plays a very important role. About 10 million deaths had occurred in the year 2020 and the cause of these deaths was cancelled. There has been an increase in the cases of cancer across the globe ever since.
The number of patients affected by cancer and the resulting death would reach 23.3 million during the forecast period. In order to treat cancer nuclear medicine has a very important role for detecting the tumors as well as the treatment of these tumors or the growth of the cells. As there is been an increase in the number of these type of diseases the market is expected to grow in the forecast period. Currently the major markets for nuclear medicine are cancer and different types of cardiovascular diseases. But the market for nuclear medicines has stopped seeing a great growth in the recent years as there has been a saturation in the market. There has been an increase in the investment for the research and developmental activities that are focusing on making use of radiopharmaceuticals in different types of diseases. Research is conducted in order to expand the use of radiopharmaceuticals in different ways.
Due to a great amount of technological development and the availability of the best healthcare infrastructure in the North American region the North American region will see a good growth in the coming years. This region is expected to have the largest market share in the coming years. The presence of various manufacturing companies of radioisotope in this region will also lead to the growth of the market in the coming years. As there has been no growth in the amount of money invested for the research and developmental activities in the North American region there shall be a good growth in the coming years. Major manufacturing units are taking better initiatives in order to expand their market.
| Report Coverage | Details |
| Market Size by 2034 | USD 35.04 Billion |
| Market Size in 2025 | USD 13.21 Billion |
| Market Size in 2024 | USD 11.85 Billion |
| Growth Rate from 2025 to 2034 | CAGR of 11.65% |
| North America Market Share in 2024 | 48% |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Product, Application, End-User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
On the basis of the product type, the diagnostic segment is expected to have the largest market share of 82% in 2024. The diagnostic segment is expected to grow due to the development of various advanced technologies which shall be helpful in detecting the illness. And as there has been an increase in the number of patients that suffer through different types of cardiovascular diseases and cancer the market for diagnostic segment is expected to grow in the coming years. There has been a great demand for the use of radioisotopes in the recent years when the demand is expected to grow by 5% in each year during the forecast period. On an average about 40 million procedures take place every year. As the number is expected to grow in the coming years the demand for diagnostics is expected to grow during the forecast period. In order to detect different types of tumors there has been advancement in the use of different types of technology. Currently there has been an increased use of radiotracers which help in the diagnosis and they have contributed largely for the growth of this market. Apart from the use of nuclear medicine in the diagnosis of various illnesses the therapeutic segment will also have a good growth in the coming years.
Followed by the diagnostic segment the therapeutic segment or the treatment segment will also have a good growth in the coming years. Due to the government intervention and the approval of various nuclear medicines there has been a commercialization of this medicine for the treatment of different types of diseases. The improved supply chain for this type of medicine and the availability of the best infrastructure for the production of these products will also drive the market growth in the coming years.
The therapeutic segment is expected to grow as there has been an increase in the production of radioisotopes. There has been an increase in the use of radiation therapy for the treatment of this type of diseases. Different types of alpha emitters are used in the therapeutics. Due to increased research and developmental activities actinium add terbium is the different types of radioisotopes that shall be used in the future for the treatment of these diseases.
On the basis of application, the oncology segment will have the largest market share in the coming years. The oncology segment is expected to have a dominant position ask answer has led to a large number of deaths across the globe. Due to different lifestyle changes and the adoption of unhealthy diet has led to an increased number of cancer deaths across the globe. Rapid urbanization has led to an increase in the number of population that smokes on a regular basis beard smoking have been one of the reasons for the onset of cancer. The sedentary lifestyle of most of the individuals working in different organizations is another leading cause for cancer. As there has been a reduction in physical exertion and increase in the consumption of junk food the oncology segment will dominate the market in the coming years. There has been an increased investment for having novel medicines for the treatment of cancer.
Constant research and development has provided with these novel medicines that will help in the growth of the segment. The cardiovascular diseases segment will also see a good growth during the forecast period as nuclear medicines are used for the diagnosis of various cardiac diseases. The availability of imaging testing that helps in detecting cardiovascular diseases have provided better growth for the market. In different healthcare setups there is an increase in the use of this system which will drive the market growth in the coming years.
Advancements in Radiopharmaceuticals
The advancements in nuclear medicine have focused on developing novel radiopharmaceuticals for targeted therapy and molecular imaging. These advancements include the use of longer-lived radioisotopes, alpha-particle emitters, and auger electron emitters, as well as the development of more effective and targeted ligands for tumor and disease-specific targets. The advancements are driving the development of personalized medicine and theragnostic approaches, combining diagnosis and treatment in a single agent.
Hybrid Imaging Systems
Hybrid imaging in nuclear medicine combines two or more imaging modalities to provide more comprehensive diagnostic information. This approach allows for the simultaneous assessment of both functional and anatomical information. This enhances the capabilities of nuclear medicine. The most common hybrid systems include PET/CT and SPECT/CT. Hybrid systems can improve the accuracy and precision of diagnoses, particularly in challenging cases by combining different imaging modalities. Hybrid systems can often improve the sensitivity and specificity of diagnoses compared to individual imaging modalities.
By Product
By Application
By End-user
By Geography
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
April 2025
June 2025
February 2025
June 2025